Overview

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Eisai Inc.
Treatments:
Cytarabine
Ondansetron
Palonosetron